TriangleNCT01207388 · OUTCOME
Resource Utilization: Duration of Hospitalization
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- days
- Interval / dispersion
- Full Range
- Time frame
- From first dose of study drug through the end of follow-up; median (minimum, maximum) time on study was 33.8 (1, 62) months.
Analysis population: Full analysis set
Groups in this outcome
Blinatumomab
Participants received blinatumomab as a continuous intravenous infusion at a constant flow rate of 15 μg/m²/day over 28 days followed by an infusion-free period of 14 days for up to 4 cycles of treatment.
| Group | Source count |
|---|---|
| Blinatumomab | 116 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Blinatumomab | 14.0 | Not reported | 3 | 63 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 3
- upper Limit
- 63
- value
- 14.0
- denoms
- counts
- group Id
- OG000
- value
- 116
- units
- Participants
- dispersion Type
- Full Range
- groups
- description
- Participants received blinatumomab as a continuous intravenous infusion at a constant flow rate of 15 μg/m²/day over 28 days followed by an infusion-free period of 14 days for up to 4 cycles of treatment.
- id
- OG000
- title
- Blinatumomab
- param Type
- MEDIAN
- population Description
- Full analysis set
- reporting Status
- POSTED
- time Frame
- From first dose of study drug through the end of follow-up; median (minimum, maximum) time on study was 33.8 (1, 62) months.
- title
- Resource Utilization: Duration of Hospitalization
- type
- SECONDARY
- unit Of Measure
- days
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice